[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: 10-ug youth (18-59 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;Group B: 25-ug youth (18-59 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;Group C: 50-ug youth (18-59 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;Group D: 10-ug elder (>=60 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;Group E: 25-ug elder (>=60 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;Group F: 50-ug elder (>=60 years) group:All subjects are given one dose of V-01 or placebo on Days 0 and 21.;", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "10\u03bcg;2;Days0-21;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "25\u03bcg;2;Days0-21;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "50\u03bcg;2;Days0-21;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]